CYP3A4*18: It is not Rare Allele in Japanese Population

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 4, 2003, Pages 267-268

  Yamamoto, Takehito ^a   Nagafuchi, Nobue ^a   Ozeki, Takeshi ^a   Kubota, Takahiro ^a   Yamada, Yasuhiko ^a   Iga, Tatsuji ^a   Ishikawa, Hiroshi ^b   Ogawa, Seishi ^c   Hirai, Hisamaru ^c  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b SRL INC   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

allele frequency; CYP3A4; CYP3A4*18; Japanese; PCR RELP

Indexed keywords

EID: 85014315005     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.267     Document Type: Article

References (6)

1. Gonzalez, F. J., Schmid, B. J., Umeno, M., McBride, O. W., Hardwick, J. P., Meyer, U. A., Gelboin, H. V. and Idle, J. R.: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA, 7: 79-86 (1988).
2. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
3. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B. and Ingelman-Sundberg, M.: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem. Biophys. Res. Commun., 259: 201-205 (1999).
4. Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W. and Goldstein, J. A.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther., 299: 825-831 (2001).
5. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V. P., Zheng, W., Raunio, H., Crespi, C. L. and Gonzalez, F. J.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther., 67: 48-56 (2000).
6. Murayama, N., Nakamura, T., Saeki, M., Soyama, A., Saito, Y., Sai, K., Ishida, S., Nakajima, O., Itoda, M., Ohno, Y., Ozawa, S. and Sawada, J.: CYP3A4 Gene Polymorphisms Influence Testosterone 6B-hydroxylation. Drug Metabo. Pharmacokin., 17: 150-156 (2002).